Intranasal delivery of therapeutic proteins for neurological diseases

Expert Opinion on Drug Delivery

Volumn 8, Issue 10, 2011, Pages 1277-1296

  Malerba, Francesca ^a,b   Paoletti, Francesca ^b   Capsoni, Simona ^a,b   Cattaneo, Antonino ^a,b  

^a SCUOLA NORMALE SUPERIORE   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

Alzheimer's disease; BBB; Biologicals; Intranasal delivery; Neurodegenerative diseases; Neurotrophins; NGF; Therapeutic antibodies

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; INSULIN; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROTROPHIC FACTOR; OREXIN A; OXYTOCIN; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENCAPSULATION; EPILEPSY; HUMAN; HUNTINGTON CHOREA; INTRANASAL DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NON INVASIVE PROCEDURE; NONHUMAN; NOSE CAVITY; OLFACTORY EPITHELIUM; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; PROTEIN DOMAIN; RESPIRATORY EPITHELIUM; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; STROKE; TRAUMATIC BRAIN INJURY; TRIGEMINAL NERVE;

ABSORPTION; ADMINISTRATION, INTRANASAL; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; PROTEINS; RESPIRATORY MUCOSA;

EID: 80053075163     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.588204     Document Type: Review

References (144)

1. Thoenen H, Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002;5:(Suppl):1046-50 (Pubitemid 35247196)
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008;7(1):21-39
3. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008;8(6):423-30
4. Reichert JM, Rosensweig CJ, Faden LB, et al. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23(9):1073-8 (Pubitemid 41486385)
5. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6(2):108-19
6. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23(9):1126-36 (Pubitemid 41486394)
7. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11(5):551-5 (Pubitemid 40691288)
8. Thorne RG, Emory CR, Ala TA, et al. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995;692(1-2):278-82
9. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57(2):178-201
10. de Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet 2007;46(7):553-76 (Pubitemid 47025357)
11. Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol 2005;30(1):57-70
12. Zlokovic BV. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res 1995;12(10):1395-406
13. Zlokovic BV, Segal MB, Davson H, et al. Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barriers. Endocrinol Exp 1990;24(1-2):9-17
14. Banks WA. The CNS as a target for peptides and peptide-based drugs. Expert Opin Drug Deliv 2006;3(6):707-12 (Pubitemid 44781843)
15. Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
16. Cattaneo A, Capsoni S, Paoletti F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J Alzheimers Dis 2008;15(2):255-83
17. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36(2):244-6 (Pubitemid 24239246)
18. Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 1996;93(9):4229-34
19. Zlokovic BV, Yamada S, Holtzman D, et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 2000;6(7):718-19 (Pubitemid 30469391)
20. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990;47(11):1210-16 (Pubitemid 20381002)
21. Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66(6):852-6 (Pubitemid 43739759)
22. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12(1-2):54-61 (Pubitemid 46014479)
23. Shipley MT. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull 1985;15(2):129-42 (Pubitemid 15017253)
24. Balin BJ, Broadwell RD, Salcman M, et al. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251(2):260-80 (Pubitemid 16027854)
25. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA 2002;99(19):12432-7
26. Capsoni S, Giannotta S, Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Mol Cell Neurosci 2002;21(1):15-28 (Pubitemid 35178496)
27. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337(1-2):1-24 (Pubitemid 46756063)
28. Morrison EE, Costanzo RM. Morphology of olfactory epithelium in humans and other vertebrates. Microsc Res Tech 1992;23(1):49-61
29. Engstrom B, Ekblom A, Hansson P. The olfactory and respiratory epithelium in Rhesus and Squirrel monkeys studied with freeze fracture technique. Acta Otolaryngol 1989;108:259-67 (Pubitemid 19240264)
30. Gopinath P, Gopinath G, Kumar TCA. Target site of intranasally sprayed substances and their transport across the nasal mucosa: a new insight into the intranasal route of drug delivery. Curr Ther Res 1978;23:596-607 (Pubitemid 8406139)
31. Perl DP, Good PF. Uptake of aluminium into central nervous system along nasal-olfactory pathways. Lancet 1987;1(8540):1028 (Pubitemid 17057868)
32. Baker H, Spencer RF. Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 1986;63(3):461-73 (Pubitemid 16036221)
33. Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481-96 (Pubitemid 38950662)
34. Thorne RG, Frey WH II. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001;40(12):907-46 (Pubitemid 34066688)
35. Mackay-Sim A. Neurogenesis in the adult olfactory neuroepithelium. Marcel Dekker, New York; 2003
36. Pollock H, Hutchings M, Weller RO, et al. Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes. J Anat 1997;191(Pt 3):337-46 (Pubitemid 27510695)
37. Bradbury MW, Cserr HF, Westrop RJ. Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit. Am J Physiol 1981;240(4):F329-36
38. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 2004;309(2):469-75 (Pubitemid 38542596)
39. Charlton ST, Whetstone J, Fayinka ST, et al. Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res 2008;25(7):1531-43
40. Chen XQ, Fawcett JR, Rahman YE, et al. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998;1(1):35-44
41. Clerico DM, To W, Lanza DC. Anatomy of the human nasal passages. Marcel Dekker, Inc., New York; 2003
42. Schaefer ML, Bottger B, Silver WL, et al. Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimuli. J Comp Neurol 2002;444(3):221-6 (Pubitemid 34117087)
43. Dufes C, Olivier JC, Gaillard F, et al. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 2003;255(1-2):87-97 (Pubitemid 36369593)
44. Thorne RG, Hanson LR, Ross TM, et al. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008;152(3):785-97
45. Hanson LR, Martinez PM, Taheri S, et al. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: A new strategy for the treatment of narcolepsy. Drug Del Tech 2004;4:66-70
46. Ross TM, Zuckermann RN, Reinhard C, et al. Intranasal administration delivers peptoids to the rat central nervous system. Neurosci Lett 2008;439(1):30-3
47. Grevers G, Herrmann U. Fenestrated endothelia in vessels of the nasal mucosa. An electron-microscopic study in the rabbit. Arch Otorhinolaryngol 1987;244(1):55-60 (Pubitemid 17083392)
48. Einer-Jensen N, Larsen L. Transfer of tritiated water, tyrosine, and propanol from the nasal cavity to cranial arterial blood in rats. Exp Brain Res 2000;130(2):216-20 (Pubitemid 30088259)
49. Skipor J, Grzegorzewski W, Einer-Jensen N, et al. Local vascular pathway for progesterone transfer to the brain after nasal administration in gilts. Reprod Biol 2003;3(2):143-59
50. Zhang ET, Richards HK, Kida S, et al. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol 1992;83(3):233-9
51. Rennels ML, Gregory TF, Blaumanis OR, et al. Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985;326(1):47-63 (Pubitemid 15160009)
52. Hadaczek P, Yamashita Y, Mirek H, et al. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006;14(1):69-78 (Pubitemid 43922142)
53. Boulton M, Flessner M, Armstrong D, et al. Contribution of extracranial lymphatics and arachnoid villi to the clearance of a CSF tracer in the rat. Am J Physiol 1999;276(3 Pt 2):R818-23 (Pubitemid 29157512)
54. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5(6):514-16 (Pubitemid 34568991)
55. Djupesland PG, Docekal P. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 2010;30(8):933-42
56. Giroux M. Controlled particle dispersion: applying vortical flow to optimize nasal drug delivery. Drug Del Tech 2007;5(3):44
57. Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2009;12(3):288-311
58. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379(1):146-57
59. Jain AK, Chalasani KB, Khar RK, et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 2007;15(6):417-27 (Pubitemid 47073057)
60. Law SL, Huang KJ, Chou VH, et al. Enhancement of nasal absorption of calcitonin loaded in liposomes. J Liposome Res 2001;11(2-3):165-74 (Pubitemid 33096376)
61. Migliore MM, Vyas TK, Campbell RB, et al. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2010;99(4):1745-61
62. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 2009;14(9):3754-79
63. Wang J, Tabata Y, Morimoto K. Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats. J Control Release 2006;113(1):31-7 (Pubitemid 43833468)
64. Miyamoto M, Natsume H, Satoh I, et al. Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int J Pharm 2001;226(1-2):127-38 (Pubitemid 32800788)
65. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009;10(2):243-9
66. Gao X, Chen J, Tao W, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm 2007;340(1-2):207-15 (Pubitemid 47043363)
67. Gao X, Tao W, Lu W, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006;27(18):3482-90
68. Gao X, Wu B, Zhang Q, et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 2007;121(3):156-67 (Pubitemid 47212537)
69. Reynoso-Camacho R, Gonzalez de Mejia E, Loarca-Pina G. Purification and acute toxicity of a lectin extracted from tepary bean (Phaseolus acutifolius). Food Chem Toxicol 2003;41(1):21-7 (Pubitemid 35346769)
70. Wan XM, Chen YP, Xu WR, et al. Identification of nose-to-brain homing peptide through phage display. Peptides 2009;30(2):343-50
71. Solomon B. Filamentous bacteriophage as a novel therapeutic tool for Alzheimer's disease treatment. J Alzheimers Dis 2008;15(2):193-8
72. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237(4819):1154-62 (Pubitemid 17124912)
73. Tuszynski MH. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21(2):179-89 (Pubitemid 46878982)
74. Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 2010;12(2):240-7
75. Cattaneo A, Capsoni S, Paoletti F. A new generation of noninvasive NGF-based therapies for Alzheimer's Disease: RSC Publishing; 2010
76. De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005;102(10):3811-16 (Pubitemid 40360709)
77. Frey IW, Liu J, Chen XQ, et al. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 1997;4:87-92 (Pubitemid 27276124)
78. Covaceuszach S, Capsoni S, Ugolini G, et al. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res 2009;6(2):158-70
79. Zhang Q, Liu Y, Yang N, et al. Nasal administration of cholera toxin B subunit-nerve growth factor improves the space learning and memory abilities in beta-amyloid protein(25-35)-induced amnesic mice. Neuroscience 2008;155(1):234-40
80. Vaka SR, Sammeta SM, Day LB, et al. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci 2009;98(10):3640-6
81. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11(8):1186-9 (Pubitemid 24259861)
82. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87(1-3):187-98 (Pubitemid 36255456)
83. Covaceuszach S, Capsoni S, Marinelli S, et al. In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V. Biochem Biophys Res Commun 2010;391(1):824-9
84. Capsoni S, Covaceuszach S, Marinelli S, et al. Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoS One 2011;6(2):e17321
85. Zhu W, Cheng S, Xu G, et al. Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv 2011 [Epub ahead of print] doi:10.3109/10717544.2011.557785
86. Lambiase A, Tirassa P, Micera A, et al. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 2005;46(10):3800-6 (Pubitemid 44264689)
87. Lambiase A, Pagani L, Di Fausto V, et al. Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: biochemical and structural evidence. Brain Res 2007;1127(1):45-51 (Pubitemid 44873000)
88. Capsoni S, Covaceuszach S, Ugolini G, et al. Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice. J Alzheimers Dis 2009;16(2):371-88
89. Di Fausto V, Fiore M, Tirassa P, et al. Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. Eur J Neurosci 2007;26(9):2473-80 (Pubitemid 350050448)
90. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med 1999;107(2B):34S-42S
91. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007;81(5-6):294-330 (Pubitemid 46528643)
92. Simonato M, Tongiorgi E, Kokaia M. Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol Sci 2006;27(12):631-8 (Pubitemid 44738088)
93. Price JL, Ko AI, Wade MJ, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58(9):1395-402 (Pubitemid 32845990)
94. Tapia-Arancibia L, Aliaga E, Silhol M, et al. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008;59(1):201-20
95. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009;15(3):331-7
96. Berardi N, Braschi C, Capsoni S, et al. BDNF intranasal administration rescues visual memory deficits in a mouse model of Alzheimer disease (AD), the AD11 mouse. FENS Forum 2008. Geneva, CH: 2008
97. Garcia P, Youssef I, Utvik JK, et al. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci 2010;30(22):7516-27
98. Alcala-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010;18(3):179-90
99. Royo NC, Conte V, Saatman KE, et al. Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4/5 in pyramidal cell neuroprotection. Eur J Neurosci 2006;23(5):1089-102
100. Nishijima T, Piriz J, Duflot S, et al. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010;67(5):834-46
101. Guerra-Crespo M, Sistos A, Gleason D, et al. Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model. J Stroke Cerebrovasc Dis 2010;19(1):3-9
102. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70(6):440-8
103. Gozes I, Giladi E, Pinhasov A, et al. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 2000;293(3):1091-8 (Pubitemid 30417880)
104. Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005;11(4):353-68
105. Macdonald K, Macdonald TM. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 2010;18(1):1-21
106. Lee HJ, Macbeth AH, Pagani JH, et al. Oxytocin: the great facilitator of life. Prog Neurobiol 2009;88(2):127-51
107. Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005;25(49):11489-93 (Pubitemid 43083720)
108. Hurlemann R, Patin A, Onur OA, et al. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J Neurosci 2010;30(14):4999-5007
109. Quirin M, Kuhl J, Dusing R. Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities. Psychoneuroendocrinology 2011 [Epub ahead of print]. doi:10.1016/j.psyneuen. 2010.12.005
110. Heinrichs M, Domes G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res 2008;170:337-50 (Pubitemid 352010240)
111. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 2010;68(7):678-80
112. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67(7):692-4
113. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003;28(1):193-8
114. Ishak WW, Berman DS, Peters A. Male anorgasmia treated with oxytocin. J Sex Med 2008;5(4):1022-4 (Pubitemid 351472217)
115. Pavlou AK, Reichert JM. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nat Biotechnol 2004;22(12):1513-19 (Pubitemid 40039448)
116. Vastag B. Monoclonals expand into neural disorders. Nat Biotechnol 2006;24(6):595-6 (Pubitemid 43884413)
117. Furrer E, Hulmann V, Urech DM. Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J Neuroimmunol 2009;215(1-2):65-72
118. Meli G, Visintin M, Cannistraci I, et al. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J Mol Biol 2009;387(3):584-606
119. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002;22(18):7873-8 (Pubitemid 35379092)
120. Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 2003;23(24):8532-8 (Pubitemid 37158753)
121. Frenkel D, Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci USA 2002;99(8):5675-9 (Pubitemid 34411609)
122. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56(1):3-17 (Pubitemid 38195323)
123. Fehm HL, Perras B, Smolnik R, et al. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur J Pharmacol 2000;405(1-3):43-54
124. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29(10):1326-34 (Pubitemid 39024358)
125. Benedict C, Hallschmid M, Schultes B, et al. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007;86(2):136-42 (Pubitemid 47494214)
126. Reger MA, Watson GS, Frey WH II, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27(3):451-8 (Pubitemid 43185331)
127. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008;13(3):323-31 (Pubitemid 352039034)
128. Merenlender-Wagner A, Pikman R, Giladi E, et al. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 2010;31(7):1368-73
129. Han IK, Kim MY, Byun HM, et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med 2007;85(1):75-83 (Pubitemid 46020944)
130. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448(7149):39-43 (Pubitemid 47037001)
131. Pulford B, Reim N, Bell A, et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One 2010;5(6):e11085
132. Bitko V, Barik S. Nasal delivery of siRNA. Methods Mol Biol 2008;442:75-82
133. Kim I, Kim SW, Lee JK. Gene Knockdown in the Olfactory Bulb, Amygdala, and Hypothalamus by Intranasal siRNA Administration. Appl Microbiol Biotechnol 2009;42(4):285-92
134. Zhao H, Otaki JM, Firestein S. Adenovirus-mediated gene transfer in olfactory neurons in vivo. J Neurobiol 1996;30(4):521-30 (Pubitemid 26256775)
135. Holtmaat AJ, Hermens WT, Oestreicher AB, et al. Efficient adenoviral vector-directed expression of a foreign gene to neurons and sustentacular cells in the mouse olfactory neuroepithelium. Brain Res Mol Brain Res 1996;41(1-2):148-56 (Pubitemid 26288155)
136. Doi K, Nibu K, Ishida H, et al. Adenovirus-mediated gene transfer in olfactory epithelium and olfactory bulb: a long-term study. Ann Otol Rhinol Laryngol 2005;114(8):629-33 (Pubitemid 41170054)
137. Draghia R, Caillaud C, Manicom R, et al. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther 1995;2(6):418-23
138. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005;94(6):1187-95 (Pubitemid 40904183)
139. Wu HM, Huang CC, Chen SH, et al. Herpes simplex virus type 1 inoculation enhances hippocampal excitability and seizure susceptibility in mice. Eur J Neurosci 2003;18(12):3294-304
140. Najioullah F, Bosshard S, Thouvenot D, et al. Diagnosis and surveillance of herpes simplex virus infection of the central nervous system. J Med Virol 2000;61(4):468-73 (Pubitemid 30450688)
141. Laing JM, Gober MD, Golembewski EK, et al. Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol Ther 2006;13(5):870-81
142. Danielyan L, Schafer R, von Ameln-Mayerhofer A, et al. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009;88(6):315-24
143. Cossu G, Bianco P. Mesoangioblasts-vascular progenitors for extravascular mesodermal tissues. Curr Opin Genet Dev 2003;13(5):537-42 (Pubitemid 37204932)
144. Binaschi A, Su T, Paradiso B, et al. Mesoangioblast-based supplementation of neurotrophic factors for the treatment of neuronal damage. Society for Neuroscience. 40th Annual Meeting 2010. San Diego, California; 2010